It’s been an eventful week for pharmaceutical and biotech industries.

Eli Lilly posted its strongest quarter ever. FDA approved two first-in-class medicines in a single day. And rumors of a possible AstraZeneca–Bristol Myers Squibb merger emerged and then were quickly refuted, but not before the story generated more questions than answers.

Here is a quick guide to everything happening.

How did Lilly perform this quarter?

Lilly posted $23 billion in second-quarter revenue — a 48% increase from the same period a year earlier — driven by a 60% increase in volume, partially offset by a 13% decline in realized prices. The company raised its full-year revenue forecast to $85 billion to $87 billion, up from the prior guidance of $82 billion to $85 billion.

What drove the results?

Mounjaro sales climbed 91% to $9.94 billion, topping analyst estimates, while Zepbound brought in $4.93 billion against expectations of $4.73 billion. Together the two drugs accounted for 64.7% of Lilly's quarterly revenue.

Are patients actually choosing injectables over pills?

Yes — by a wide margin. Demand for injectable GLP-1 medicines remained strong, accounting for roughly three out of every four new patient starts even as oral obesity options have entered the market. In the Medicare obesity drug pilot that launched last month, about 80% of patients chose to begin treatment with an injectable medicine.

What about Lilly's new obesity pill?

Sales of Foundayo, Lilly's newly launched once-daily obesity pill, totaled $98 million, coming in short of the $105.6 million analysts had expected. Prescriptions in the last week of July were nearly doubling those from a month earlier, with nearly one in four patients beginning treatment on the pill. Foundayo is now under regulatory review in more than 40 markets, with Lilly expecting a rollout across all major markets in 2027.

What is Orzeyful and why does it matter?

FDA approved Takeda's Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults — making it the first oral orexin receptor 2 agonist approved for the disease. Until now, treatments for narcolepsy type 1 focused on managing individual symptoms. Orzeyful is the only medicine indicated in the US to treat the disease holistically rather than targeting individual symptoms, addressing the underlying orexin deficiency that drives the condition.

When will Orzeyful be available?

The controlled substance classification for Orzeyful is currently under review by the DEA and is expected within 90 days. After that determination, Orzeyful is expected to be made available through a specialty pharmacy.

What is the new Moderna flu vaccine and who can get it?

FDA approved mFLUSIVA (mRNA-1010), Moderna's mRNA-based influenza vaccine, for adults 50 years and older. Moderna expects supply to be available at select retailers ahead of the 2026–2027 respiratory virus season. It is Moderna's fourth FDA-approved product and the first mRNA-based flu vaccine.

How effective is it?

The approval for adults 50 through 64 was based on a Phase 3 trial enrolling 40,805 adults across 11 countries. mFLUSIVA demonstrated a relative vaccine efficacy of 26.6% versus a standard-dose comparator. Among adults 65 and older, relative vaccine efficacy reached 27.4%. The approval for adults 65 and older was granted under accelerated approval, meaning a confirmatory postmarketing trial is required.

Are AstraZeneca and BMS actually merging?

The short answer: unclear, and getting less clear by the day. Reports of merger discussions emerged Monday, sending AstraZeneca shares down as much as 7% while Bristol Myers gained roughly 6% in US premarket trading. But a senior AstraZeneca source subsequently denied the talks to the Financial Times, telling the publication the company is not in discussions with Bristol Myers Squibb. Neither company has made an official statement.

So where does that leave things?

In a holding pattern. The denial came from a senior source rather than from the company officially, and merger rumors of this scale — involving a potential $400 billion combination that would create the world's largest pharmaceutical company by revenue — rarely disappear after a single denial. Analysts remain divided on whether the talks happened, and if so, how serious they were. What is not in dispute is that the story has focused significant industry attention on the strategic positions of both companies.

If a deal were to happen, what would it mean strategically?

According to Thani Jambulingam, PhD, of Saint Joseph's University, the financial rationale differs for each company. For BMS, the strategic imperative is clear: secure future growth, as the company faces a well-understood patent cycle where products that have generated extraordinary shareholder value will encounter biosimilar or generic competition. AstraZeneca, however, does not appear to require a transformational acquisition to sustain near-term growth — which raises a more interesting question.

So why would AstraZeneca even consider it?

Jambulingam's argument is that the deal is less about financial engineering and more about building capabilities for the next phase of competition. The pharmaceutical industry is entering a period in which competitive leadership will increasingly depend on an organization's ability to integrate AI, manufacturing resilience, regulatory intelligence, market access, digital health, real-world evidence, and global supply chain management — capabilities that are no longer supporting activities but are becoming strategic differentiators.

What would a combined company actually look like?

AstraZeneca would contribute sustained revenue growth, broad therapeutic diversification, geographic balance, and one of the industry's strongest innovation trajectories. BMS would contribute exceptional cash generation, deep oncology expertise, one of the strongest commercial infrastructures in the United States, extensive payer relationships, and decades of clinical development experience. These assets are complementary rather than redundant.

What's the bottom line on the AZ-BMS story?

Whether or not a deal materializes — or ever existed — the discussion itself is significant. As Jambulingam puts it, the AstraZeneca–BMS story may ultimately be remembered less as the industry's largest proposed merger than as one of its earliest signals that the rules of pharmaceutical competition had fundamentally changed. The denial doesn't close that conversation. It just moves it to the next chapter.